BioSyent Inc. (BIOYF)
| Previous Close | 6.32 |
| Open | 6.24 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 6.24 - 6.33 |
| 52 Week Range | 5.26 - 6.97 |
| Volume | |
| Avg. Volume | 1,632 |
| Market Cap | 73.447M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | 16.23 |
| EPS (TTM) | 0.39 |
| Earnings Date | May 24, 2024 - May 28, 2024 |
| Forward Dividend & Yield | 0.13 (2.10%) |
| Ex-Dividend Date | Feb 28, 2024 |
| 1y Target Est | N/A |
- ACCESSWIRE
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las ...
GlobeNewswireBioSyent to Attend Planet MicroCap Showcase
MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th – May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent, will attend a Fireside Q&A session for investors at the conference on Wednesday, May 1st at 2:30pm PDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during th
- GlobeNewswire
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032. “RepaGyn® and Proktis-M® have been part of our product portfolio since
